PINOVA THERAPEUTICS
Live / Registered — Registered (as of 02 Jun 2026)
What this means for you
Registered since 02 Jun 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 02 Jun 2032: the §8 declaration of use).
Record
- Serial number
- 97135396
- Registration number
- 8285284
- Mark type
- Word mark
- Filed
- 19 Nov 2021
- Published for opposition
- 18 Jul 2023
- Registered
- 02 Jun 2026
- Next maintenance filing
- §8 declaration of use, due by 02 Jun 2032 (grace period to 02 Dec 2032)
- Attorney of record
- Spencer Wolff Esquire
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy side effects, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
- Class 042 — Scientific and technological services: scientific research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
- Class 044 — Medical, beauty and agricultural services: medical and healthcare information services namely providing medical and healthcare information in the fields of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
Owner
- Pocket Naloxone Corp., Bethesda, MD, US
- Pocket Naloxone Corp., Bethesda, MD, US
- Pocket Naloxone Corp., Bethesda, MD, US
Prosecution history
- 02 Jun 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 02 Jun 2026 — REGISTERED-PRINCIPAL REGISTER
- 11 May 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 11 May 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 11 Apr 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 17 Oct 2025 — USE AMENDMENT FILED
- 06 Apr 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 17 Oct 2025 — TEAS STATEMENT OF USE RECEIVED
- 17 Oct 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 17 Oct 2025 — NOTICE OF REVIVAL - E-MAILED
- 17 Oct 2025 — PETITION TO REVIVE-GRANTED
- 17 Oct 2025 — TEAS PETITION TO REVIVE RECEIVED
- 13 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 13 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 20 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED